American Century Companies Inc. Sells 203,328 Shares of Repligen Co. (NASDAQ:RGEN)

American Century Companies Inc. trimmed its holdings in Repligen Co. (NASDAQ:RGEN) by 40.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 296,245 shares of the biotechnology company’s stock after selling 203,328 shares during the period. American Century Companies Inc. owned 0.53% of Repligen worth $37,345,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Evoke Wealth LLC acquired a new position in Repligen in the 4th quarter valued at $1,955,000. Norden Group LLC raised its stake in Repligen by 1,711.6% in the first quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock valued at $7,137,000 after purchasing an additional 36,663 shares in the last quarter. Artemis Investment Management LLP lifted its position in Repligen by 33.8% during the first quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after purchasing an additional 42,380 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Repligen by 30.2% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after buying an additional 6,705 shares in the last quarter. Finally, Congress Asset Management Co. MA increased its holdings in Repligen by 14.6% in the 1st quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock valued at $16,187,000 after buying an additional 11,213 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Repligen Stock Performance

NASDAQ:RGEN opened at $136.39 on Wednesday. The stock’s 50-day moving average is $146.15 and its 200-day moving average is $156.04. The stock has a market cap of $7.62 billion, a P/E ratio of 545.56, a price-to-earnings-growth ratio of 4.20 and a beta of 0.94. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. During the same quarter last year, the firm earned $0.53 earnings per share. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. Equities research analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on RGEN. UBS Group cut their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Stephens reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. Wells Fargo & Company began coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. Finally, Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $188.38.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.